multiple sclerosis

(redirected from relapsing-remitting multiple sclerosis)
Also found in: Dictionary, Thesaurus, Medical.

multiple sclerosis

(MS), chronic, slowly progressive autoimmune disease in which the body's immune system attacks the protective myelin sheaths that surround the nerve cells of the brain and spinal cord (a process called demyelination), resulting in damaged areas that are unable to transmit nerve impulses. The disease also gradually damages the nerves themselves. There are elevated numbers of lymphocytes in the cerebral spinal fluid and of T cells in the blood (see immunityimmunity,
ability of an organism to resist disease by identifying and destroying foreign substances or organisms. Although all animals have some immune capabilities, little is known about nonmammalian immunity.
..... Click the link for more information.
).

The onset of MS is usually at age 20 to 40 years, and its many symptoms affect almost every system of the body. There may be visual difficulties, emotional disturbances, speech disorders, convulsions, paralysis or numbness of various regions of the body, bladder disturbances, and muscular weakness. The course of the disease varies greatly from person to person. In some patients, the symptoms remit and return, sometimes at frequent intervals and sometimes after several years. In others the disease progresses steadily.

There is a genetic predisposition to MS, and environmental factors also seem to play some role. The disease is more common in temperate climates (1:2,000) than in the tropics (1:10,000).

There is no cure for MS, but a number of drugs—the first of which became available in the 1990s—can slow its underlying progress and/or reduce the frequency of attacks. These are beta interferon (a synthetic version of a natural substance produced by the immune system), glatiramer acetate, and natalizumab.

Bibliography

See R. Rubinstein, Take It Or Leave It: Aspects of Being Ill (1989); U.S. Dept. of Health and Human Services, Warren Grant Magnuson Clinical Center, Multiple Sclerosis (1990).

Multiple Sclerosis

 

a chronic progressive disease of man, characterized by the development of foci of demyelination in the central and peripheral nervous systems; a neurological disease. The etiology is not clear; according to the infectious allergic theory, an infectious (viral or bacterial) agent initiates a prolonged autoimmune process.

In multiple sclerosis, sclerotic patches of varying sizes form in the matter of the brain and spinal cord. Microscopic examination reveals demyelination and proliferation of glia in these patches. The disease usually develops at an early age. In 1868, J. M. Charcot described the classic triad of symptoms: nystagmus, intention tremor (irregular oscillations of the eyes occurring when the patient moves), and staccato speech. Also characteristic are visual disturbances (changes in the fields of color perception, changes in acuteness of vision, and double vision); disturbances of the vestibular apparatus (dizziness); impairment of coordination; changes in the pyramidal system (spastic paresis of the lower extremities, pathologic Babinski’s and Ros-solimo’s reflexes, and loss of abdominal reflexes); disturbances in vibration sensitivity; and changes in the cerebrospinal fluid. The course of the disease is slow, and there are usually recurrent exacerbations; in time, the periods of remission become shorter and the neurological symptoms progress.

Multiple sclerosis is treated with desensitizing agents, immunosuppressants (chloroquine phosphate, glucocorticoids, cyclophosphamide, and histaglobin), transfusions of blood and blood substitutes, and drugs that normalize metabolism, vitamin balance, and neurohumoral influences (ATP, B-complex vitamins, glutamic acid, neostigmine methyl sulfate, and diethazine). Other methods of treatment include physiotherapy (electric sleep, applications of ozokerite, inductothermy), exercise therapy, and bioelectric stimulation of muscles and coordination of movements. Research is being conducted on methods of surgical treatment of multiple sclerosis.

REFERENCES

Demieliniziruiushchie zabolevaniia nervnoi sistemy v eksperimente i klinike. Minsk, 1970.
Panov, A. G., and A. P. Zinchenko. Diagnostika rasseiannogo skleroza i entsefalomielita. [Leningrad] 1970.
Pentsik, A. S. Rasseiannyi skleroz. Riga, 1970.

V. B. GEL’FAND

multiple sclerosis

[′məl·tə·pəl sklə′rō·səs]
(medicine)
A degenerative disease of the nervous system of unknown cause in which there is demyelination followed by gliosis.

multiple sclerosis

a chronic progressive disease of the central nervous system characterized by loss of some of the myelin sheath surrounding certain nerve fibres and resulting in speech and visual disorders, tremor, muscular incoordination, partial paralysis, etc.
References in periodicals archive ?
The company said MAVENCLAD is recommended for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability or who are unable to tolerate, one or more therapies for multiple sclerosis.
Health care company Bayer revealed on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator for patients with relapsing-remitting multiple sclerosis, a chronically inflammatory, incurable and usually intermittent disease of the central nervous system.
An immune-suppressing agent for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.
In a two-year study of 148 patients with relapsing-remitting multiple sclerosis (MS), researchers found that those who received monthly intravenous infusions of a substance called immunoglobulin had their symptoms improve, compared with those who received placebo.
Today Biogen Idec (NASDAQ: BIIB) announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.
Results showed that Gilenya impacted four key measures of MS disease activity (relapses, MRI lesions, disability progression and brain shrinkage) in people with relapsing-remitting multiple sclerosis (RRMS) for up to 16 months.
Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: subgroup analyses by previous DMT use (Poster Session 1 - P483; October 11; 3:30 p.
The company said the decline in the Q3 2016 was related to a reduction in the use of contract manufacturers and clinical research organisations during its evaluation of options for an alternative Phase 3 clinical plan for FP187 in relapsing-remitting multiple sclerosis (RRMS)
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on the opinions of interviewed thought leaders and currently available clinical data, Biogen Idec's emerging oral disease-modifying therapy BG-12 will earn Decision Resources' proprietary clinical gold standard status for the treatment of relapsing-remitting multiple sclerosis in 2015.
RedHill Biopharma (NASDAQ / TASE: RDHL), an Israeli biopharmaceutical company, has completed the last dosing and scheduled follow-up patient visit ahead of top-line interim analysis in the Phase IIa proof-of-concept clinical study assessing RHB-104 in patients treated for relapsing-remitting multiple sclerosis, it was reported yesterday.
Today Biogen Idec (NASDAQ: BIIB) announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS).